Potent anticancer activity of a new bismuth (III) complex against human lung cancer cells

Cytotoxicity of bismuth(III) dithiocarbamate derivatives by promoting a mitochondrial-dependent apoptotic pathway and suppressing MCF-7 breast adenocarcinoma cell invasion

We previously reported that the bismuth(III) dithiocarbamate derivative, bismuth diethyldithiocarbamate (1) exhibited greater cytotoxicity while inducing apoptosis via the intrinsic pathway in MCF-7 cells. We further evaluated the other bismuth(III) dithiocarbamate derivatives, Bi[S2CNR]3, with R = (CH2CH2OH)(iPr), (CH2)4, and (CH2CH2OH)(CH3), denoted as 2, 3, and 4, respectively, in the same MCF-7 cell line. 2-4 were found to exhibit IC50 values of 10.33 ± 0.06 µM, 1.07 ± 0.01 µM and 25.37 ± 0.12 µM, respectively, compared to that of cisplatin at 30.53 ± 0.23 µM. Apoptotic promotion via the mitochondrial-dependent pathway was due to the elevation of intracellular reactive oxygen species (ROS), promotion of caspases, release of cytochrome c, fragmentation of DNA, and results of staining assay observed in all compound-treated cells. 2-4 are also capable of suppressing MCF-7 cell invasion and modulate Lys-48 also Lys-63 linked polyubiquitination, leading to proteasomal degradation. Analysis of gene expression via qRT-PCR revealed their modulation, which supported all activities conducted upon treatment with 2-4. Altogether, bismuth dithiocarbamate derivatives, with bismuth(III) as the metal center bound to ligands, isopropyl ethanol, pyrrolidine, and methyl ethanol dithiocarbamate, are potential anti-breast cancer agents that induce apoptosis and suppress metastasis. Further studies using other breast cancer cell lines and in vivo studies are recommended to clarify the anticancer effects of these compounds.

Biological Activities of Bismuth Compounds: An Overview of the New Findings and the Old Challenges Not Yet Overcome

Bismuth-based drugs have been used primarily to treat ulcers caused by Helicobacter pylori and other gastrointestinal ailments. Combined with antibiotics, these drugs also possess synergistic activity, making them ideal for multiple therapy regimens and overcoming bacterial resistance. Compounds based on bismuth have a low cost, are safe for human use, and some of them are also effective against tumoral cells, leishmaniasis, fungi, and viruses. However, these compounds have limited bioavailability in physiological environments. As a result, there is a growing interest in developing new bismuth compounds and approaches to overcome this challenge. Considering the beneficial properties of bismuth and the importance of discovering new drugs, this review focused on the last decade's updates involving bismuth compounds, especially those with potent activity and low toxicity, desirable characteristics for developing new drugs. In addition, bismuth-based compounds with dual activity were also highlighted, as well as their modes of action and structure-activity relationship, among other relevant discoveries. In this way, we hope this review provides a fertile ground for rationalizing new bismuth-based drugs.

Potent saccharinate-containing palladium(II) complexes for sensitization to cancer therapy

Palladium(II) (Pd^II) complexes are among the most promising anticancer compounds. Both 2`-benzoylpyridine thiosemicarbazone (BpT) and saccharinate (Sac) are efficient metal chelators with potent anticancer activity. To explore a more effective new anticancer drug, we synthesized a series of Sac and BpT-containing Pd^II complexes coordinated with thiosemicarbazone (TSC)-derived ligands, and characterized them through nuclear magnetic resonance (NMR), Fourier transformed infrared spectroscopy (FT-IR), elemental analysis, ultraviolet-visible spectroscopy (UV-Vis) and thermogravimetric analysis (TGA). Each target complex was composed of Pd^II, BpT, and one or two Sac molecules. Both the in vitro and in vivo anti-growth effects of those ligands and the obtained Pd^II complexes were investigated in the human lung adenocarcinoma cell lines A549 and Spc-A1. The coordination of Pd^II with the TSC-derivatives and Sac resulted in clearly greater anticancer activity than single ligands. These compounds were demonstrated to be safe for 293 T normal human kidney epithelial cells. The introduction of Sac into the TSC-derived Pd^II complex significantly enhanced anti-growth effects, and induced apoptosis of human lung cancer cells in vitro and in vivo in a dose dependent manner. Moreover, the Pd^II complex containing two Sac molecules showed the most promising therapeutic effects, thereby confirming that Sac increases the cancer therapeutic efficacy of Pd^II complexes and providing a new strategy for exploring anticancer drugs for potential clinical treatment.

Advances in thiosemicarbazone metal complexes as anti-lung cancer agents

The great success of cisplatin as a chemotherapeutic agent considerably increased research efforts in inorganic biochemistry to identify more metallic drugs having the potential of treating lung cancer. Metal coordination centres, which exhibit a wide range of coordination numbers and geometries, various oxidised and reduced states and the inherent ligand properties offer pharmaceutical chemists a plethora of drug structures. Owing to the presence of C=N and C=S bonds in a thiosemicarbazone Schiff base, N and S atoms in its hybrid orbital has lone pair of electrons, which can generate metal complexes with different stabilities with most metal elements under certain conditions. Such ligands and complexes play key roles in the treatment of anti-lung cancer. Research regarding metallic anti-lung cancer has advanced considerably, but there remain several challenges. In this review, we discuss the potential of thiosemicarbazone Schiff base complexes as anti-lung cancer drugs, their anti-cancer activities and the most likely action mechanisms involving the recent families of copper, nickel, platinum, ruthenium and other complexes.

Bistratal Au@Bi2S3 nanobones for excellent NIR-triggered/multimodal imaging-guided synergistic therapy for liver cancer

To fabricate a highly biocompatible nanoplatform enabling synergistic therapy and real-time imaging, novel Au@Bi2S3 core shell nanobones (NBs) (Au@Bi2S3 NBs) with Au nanorods as cores were synthesized. The combination of Au nanorods with Bi2S3 film made the Au@Bi2S3 NBs exhibit ultrahigh photothermal (PT) conversion efficiency, remarkable photoacoustic (PA) imaging and high computed tomography (CT) performance; these Au@Bi2S3 NBs thus are a promising nanotheranostic agent for PT/PA/CT imaging. Subsequently, poly(N-vinylpyrrolidone)-modified Au@Bi2S3 NBs (Au@Bi2S3-PVP NBs) were successfully loaded with the anticancer drug doxorubicin (DOX), and a satisfactory pH sensitive release profile was achieved, thus revealing the great potential of Au@Bi2S3-PVP NBs in chemotherapy as a drug carrier to deliver DOX into cancer cells. Both in vitro and in vivo investigations demonstrated that the Au@Bi2S3-PVP NBs possessed multiple desired features for cancer therapy, including extremely low toxicity, good biocompatibility, high drug loading ability, precise tumor targeting and effective accumulation. Highly efficient ablation of the human liver cancer cell HepG2 was achieved through Au@Bi2S3-PVP NB-mediated photothermal therapy (PTT). As both a contrast enhancement probe and therapeutic agent, Au@Bi2S3-PVP NBs provided outstanding NIR-triggered multi-modal PT/PA/CT imaging-guided PTT and effectively inhibited the growth of HepG2 liver cancer cells via synergistic chemo/PT therapy.

Fluorescence Sensors for Bismuth (III) Ion from Pyreno[4,5-d]imidazole Derivatives

Three pyreno[4,5-d]imidazole derivatives are synthesized and evaluated as fluorescent sensors for bismuth (III) ion. The target compounds are prepared in 55-86% yields from a condensation reaction between pyrene-4,5-dione and aromatic aldehydes. The compound bearing a phenolic group can selectively detect bismuth (III) ion via fluorescence enhancement with a detection limit of 1.20 μm in CH₃ CN-DMSO mixture and 3.40 μm in 10% pH5 aqueous in CH₃ CN-DMSO mixture. The sensing mechanism involving a formation of coordination complex is investigated by UV-VIS and fluorescence titrations, ¹ H-NMR and the decomplexation of the bismuth complex by sulfide ion. The application of this sensor for quantitative analysis of spiked bismuth (III) ion in real water samples from two different sources is demonstrated.

Using non-combustion explosion in H2O/DMF to synthesize 3D Structure of ultrathin Bi nanofilm with high catalytic activity for p-nitrophenol reduction

The synthesis of inorganic micro-/nano-materials by dry combustion is somewhat dangerous since it is performed under high temperature. The ultrathin Bi nanofilms with 3D structures were synthesized using a safe approach of non-combustion explosion in H₂O/DMF solution at room temperature and atmospheric pressure. The violent reaction between H₂O₂ and NH₃ · H₂O resulted in a non-combustion explosion due to the fast evolution of gases. Then under high temperature and high pressure during solvothermal process, the further slight explosion occurred where the oxygen-containing molecules of H₂O₂ and NO₃ ^- acted as oxidants, while the hydrogen-containing molecules of NaBH₄, NH₃ · H₂O and DMF acted as reductants. The release of gases was accompanied with Bi^III reduction by NaBH₄. The 3D structure of ultrathin Bi nanofilms with many void spaces formed due to the explosive force and foams from the sharp liberation of gases. Such ultrathin Bi nanofilms with 3D structure exhibited outstanding catalytic activity for p-nitrophenol hydrogenation which is important to treat the environmental pollution from p-nitrophenol discharge. Within only several seconds p-nitrophenol hydrogenation was completed without delay. The non-combustion explosion exhibits potential applications for the synthesis of 3D ultrathin film materials as high efficient catalysts.

Versatile Colorimetric Chemosensor Based on Bis(rhodamine) B Hydrazone for Rapid Detection of Multi-Analytes (Fe3+, Bi3+, Cu2+, and Hg2+) in Aqueous Media

A new bis(rhodamine) B hydrazone L, bearing two rhodamine chromophores, has been designed and synthesised in 70% yield. The chemical structure of the new ligand L was characterised using different spectroscopic techniques. The receptor L was utilised for rapid ‘naked eye’ detection of Fe3+, Bi3+, Cu2+, and Hg2+ in THF–H2O (1:1, v/v) by displaying significant colour changes. The mechanism of detection of metal ions was based on the ring-opening of the spirolactam rings of L upon recognition. UV/Vis spectrometry was employed to investigate L–metal ion interactions in THF–H2O (1:1, v/v). The stoichiometries of the complexes were determined using Job’s method, which revealed 1:2L–metal ion stoichiometries in the case of L–(Fe3+/Bi3+/Hg2+) complexes, while a 1:1L–metal ion stoichiometry was recognised for the L–Cu2+ complex. 1H NMR spectroscopy was applied to study the L–metal ion interactions in DMSO-d6 and results are presented.

An efficient new dual fluorescent pyrene based chemosensor for the detection of bismuth (III) and aluminium (III) ions and its applications in bio-imaging

A new simple pyrene based schiff base chemosensor 1 (nicotinic acid pyren-1-ylmethylene-hydrazide) has been constructed and is prepared from 1-pyrenecarboxaldehyde and nicotinic hydrazide. Notably, the chemosensor 1 exhibited remarkable colour changes while in the presence of trivalent metal ions like Bi³⁺ & Al³⁺ ion in DMSO-H₂O, (1:1 v/v, HEPES = 50 mM, pH = 7.4). The UV-Vis spectral investigation of chemosensor 1 showed that the maximum absorption peak appeared at 378 nm. In emission studies, chemosensor 1 develops weak fluorescence, while upon the addition of Bi³⁺ and Al³⁺ ions, it exhibits an enhancement of fluorescence intensity. Nevertheless, rest of metal ions have no changes in the emission spectra. The association constant of chemosensor 1 for binding to Bi³⁺ & Al³⁺ system had a value of 1.27 × 10⁴ M^-1 and 1.53 × 10⁴ M^-1. The detection limits were 0.12 µM for Bi³⁺ and 0.17 µM for Al³⁺ respectively. The overall results reveal that chemosensor 1 can act as a dual-channel, highly selective, and sensitive probe for Bi³⁺ and Al³⁺ ions. Moreover, the fluorescence imaging of chemosensor 1 was applied in RAW 264.7 cell line and cytotoxicity assay prove that this chemosensor 1 is non-toxic as well as highly biocompatible.

Synthesis, structural and antimicrobial studies of binary and ternary complexes of a new tridentate thiosemicarbazone

A new thiosemicarbazone ligand was synthesized and characterized using spectroscopic techniques (UV-Vis and IR) and synchrotron x-ray powder diffraction. With M²⁺ = Mn²⁺, Zn²⁺ and Cd²⁺, coordination compounds of the type (M[L]₂) were isolated. In the presence of sodium dithiocarbamate salts (NadiEtdtc.3H₂O = sodium diethyldithiocarbamate trihydrate and Napipdtc = sodium piperidinedithiocarbamate), Zn²⁺ and Cd²⁺ were able to form ternary octahedral complexes where each metal binds a deprotonated (thiosemicarbazone) ligand, a monobasic dithiocarbamate ligand and a water molecule. In vitro biological evaluation tests of the free HL ligand and its metal complexes against selected fungal and bacterial cultures were performed. Compared with HL, the complexes displayed enhanced biological activities and ternary Zn (II) complexes displayed comparable antibacterial activities to the chloramphenicol standard.

Preparation and cytocompatibility of a novel bismuth aluminate/calcium phosphate cement with high radiopacity

In a minimally invasive surgery, using a bone cement being radiologically detectable is vital to the success of the procedure and avoiding cement leakage in the early stage. The radiopacity of calcium phosphate cement (CPC) is inadequate, thus limiting its clinic application in this area. In this work, bismuth aluminate (BiA) was employed as a radiopaque agent for CPC. The influences of BiA on physicochemical, radiopaque and in vitro biocompatible properties of CPC were investigated. With the increasing content of BiA, the setting time and the compressive strength of CPC were augmented, while the injectability of the cement pastes was reduced. The radiopacity of CPC was significantly improved by adding more than 6 wt.% BiA. CPC specimens with less than 12 wt.% BiA showed good cellular affinity. Moreover, the CPC containing 6 and 9 wt.% BiA promoted the cell growth and ALP activity of mouse bone marrow mesenchymal stem cells when compared with the control. On the basis of its improved radiopacity and cytocompatibility, the radiopaque CPC with 6 ~ 9 wt.% BiA is expected to be a potential substitute for bone defect restoration via minimally invasive surgery. CPC with bismuth aluminate reveals better radiopacity and cell affinity along with proper physicochemical properties.

Cytotoxicity of biologically synthesised bismuth nanoparticles against HT-29 cell line

This study was purposed to examine the cytotoxicity and functions of biologically synthesised bismuth nanoparticles (Bi NPs) produced by Delftia sp. SFG on human colon adenocarcinoma cell line of HT-29. The structural properties of Bi NPs were investigated using transmission electron microscopy, energy dispersive X-ray, and X-ray diffraction techniques. The cytotoxic effects of Bi NPs were analysed using flow cytometry cell apoptosis while western blot analyses were applied to analyse the cleaved caspase-3 expression. Oxidative stress (OS) damage was determined using the measurement of the glutathione (GSH) and malondialdehyde (MDA) levels and antioxidant activity of superoxide dismutase (SOD) and catalase (CAT) levels. The half maximal inhibitory concentration (IC50) value of Bi NPs was measured to be 28.7 ± 1.4 µg/ml on HT-29 cell line. The viability of HT-29 represented a concentration-dependent pattern (5-80 µg/ml). The mode of Bi NPs induced apoptosis was found to be mainly related to late apoptosis or necrosis at IC50 concentration, without the effect on caspase-3 activities. Furthermore, Bi NPs reduced the GSH and increased the MDA levels and decreased the SOD and CAT activities. Taken together, biogenic Bi NPs induced cytotoxicity on HT-29 cell line through the activation of late apoptosis independent of caspase pathway and may enhance the OS biomarkers.